Amarin expects positive full-year 2026 cash flow as VASCEPA market share reaches 48% and Europe demand rises 69% (NASDAQ:AMRN)
· seekingalpha.com
Amarin (AMRN) Q2 2026 earnings call recap: restructuring done, 2026 cash-flow outlook, VASCEPA/VAZKEPA demand, Europe reimbursement risks—read more.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...